BRPI0711136A2 - uso de timosina alfa1, isoladamente ou em combinação com ptx3 ou ganciclovir, para o tratamento de infeção por citomegalovìrus - Google Patents
uso de timosina alfa1, isoladamente ou em combinação com ptx3 ou ganciclovir, para o tratamento de infeção por citomegalovìrus Download PDFInfo
- Publication number
- BRPI0711136A2 BRPI0711136A2 BRPI0711136-3A BRPI0711136A BRPI0711136A2 BR PI0711136 A2 BRPI0711136 A2 BR PI0711136A2 BR PI0711136 A BRPI0711136 A BR PI0711136A BR PI0711136 A2 BRPI0711136 A2 BR PI0711136A2
- Authority
- BR
- Brazil
- Prior art keywords
- ganciclovir
- treatment
- combination
- ptx3
- alfa1
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Marine Sciences & Fisheries (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
USO DE TIMOSINA ALFA1, ISOLADAMENTE OU EM COMBINAçãO COM PTX3 OU GANCICLOVIR, PARA O TRATAMENTO DE INFECçãO POR CITOMEGALOVìRUS. A presente invenção refere-se ao uso de timosina alfa 1 em combinação com pentraxina PTX3 longa ou ganciclovir, para a preparação de um medicamento para a prevenção ou o tratamento de doenças virais e/ou para a inibição de ativação de vírus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06113401 | 2006-05-02 | ||
PCT/EP2007/053574 WO2007128647A1 (en) | 2006-05-02 | 2007-04-12 | USE OF THYMOSIN α1, ALONE OR IN COMBINATION WITH PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0711136A2 true BRPI0711136A2 (pt) | 2011-08-30 |
Family
ID=36658736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0711136-3A BRPI0711136A2 (pt) | 2006-05-02 | 2007-04-12 | uso de timosina alfa1, isoladamente ou em combinação com ptx3 ou ganciclovir, para o tratamento de infeção por citomegalovìrus |
Country Status (19)
Country | Link |
---|---|
US (1) | US8337828B2 (pt) |
EP (1) | EP2012816B1 (pt) |
JP (1) | JP5441685B2 (pt) |
KR (1) | KR101380360B1 (pt) |
CN (1) | CN101437535B (pt) |
AU (1) | AU2007247292B2 (pt) |
BR (1) | BRPI0711136A2 (pt) |
CA (1) | CA2649063C (pt) |
CY (1) | CY1113277T1 (pt) |
DK (1) | DK2012816T3 (pt) |
ES (1) | ES2389452T3 (pt) |
HK (1) | HK1128622A1 (pt) |
HR (1) | HRP20120676T1 (pt) |
MX (1) | MX2008013872A (pt) |
PL (1) | PL2012816T3 (pt) |
PT (1) | PT2012816E (pt) |
RS (1) | RS52377B (pt) |
SI (1) | SI2012816T1 (pt) |
WO (1) | WO2007128647A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1298487B1 (it) * | 1997-12-19 | 2000-01-10 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
ITRM20040223A1 (it) * | 2004-05-07 | 2004-08-07 | Sigma Tau Ind Farmaceuti | Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi. |
EP1832295A1 (en) * | 2006-03-10 | 2007-09-12 | Tecnogen S.P.A. | Use of PTX3 for the treatment of viral diseases |
US8829173B2 (en) * | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
US8716012B2 (en) * | 2009-05-08 | 2014-05-06 | Sciclone Pharmaceuticals, Inc. | Alpha thymosin peptides as vaccine enhancers |
CN103458681A (zh) * | 2011-02-09 | 2013-12-18 | 赛生制药有限公司 | 用于预防感染、降低感染的严重性、及治疗感染的胸腺素α肽 |
EP2909324B1 (en) | 2012-10-25 | 2020-02-26 | Tocagen Inc. | Retroviral vector with mini-promoter cassette |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6106868A (en) * | 1990-08-24 | 2000-08-22 | The Board Of Governors Of Wayne State University | Method for the treatment of hepatitis |
TW224053B (pt) | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
CN1072961C (zh) * | 1993-03-05 | 2001-10-17 | 施塞克龙药品公司 | 治疗对干扰素治疗无反应者的丙型肝炎的方法 |
US6200952B1 (en) * | 1993-06-02 | 2001-03-13 | Sciclone Pharmaceuticals, Inc. | Combination therapy method for treating chronic hepatitis B |
US5632983A (en) * | 1994-11-17 | 1997-05-27 | University Of South Florida | Method for treating secondary immunodeficiency |
CA2270223A1 (en) * | 1996-10-28 | 1998-05-07 | Carson B. Burgstiner (Deceased) | Methods and compositions for dietary supplementation |
US5939423A (en) * | 1997-04-16 | 1999-08-17 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir |
IT1298487B1 (it) * | 1997-12-19 | 2000-01-10 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
US6288033B1 (en) * | 1998-09-25 | 2001-09-11 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir |
IT1317927B1 (it) | 2000-11-03 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni. |
IT1317930B1 (it) | 2000-11-08 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione |
JP4312599B2 (ja) | 2001-08-03 | 2009-08-12 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | 女性の不妊治療のための長いペントラキシンptx3の使用 |
WO2003035111A1 (en) * | 2001-10-24 | 2003-05-01 | Sciclone Pharmaceuticals, Inc. | Antiretroviral compositions comprising thymosin alpha peptides and protease inhibitors |
WO2004094991A2 (en) * | 2003-04-23 | 2004-11-04 | Sciclone Pharmaceuticals, Inc. | Treatment or prevention of respiratory viral infections with alpha thymosin peptides |
ITRM20030596A1 (it) | 2003-12-23 | 2005-06-24 | Sigma Tau Ind Farmaceuti | Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3. |
EP1832295A1 (en) * | 2006-03-10 | 2007-09-12 | Tecnogen S.P.A. | Use of PTX3 for the treatment of viral diseases |
-
2007
- 2007-04-12 BR BRPI0711136-3A patent/BRPI0711136A2/pt not_active IP Right Cessation
- 2007-04-12 KR KR1020087029405A patent/KR101380360B1/ko not_active IP Right Cessation
- 2007-04-12 PT PT07728041T patent/PT2012816E/pt unknown
- 2007-04-12 JP JP2009508294A patent/JP5441685B2/ja not_active Expired - Fee Related
- 2007-04-12 SI SI200730976T patent/SI2012816T1/sl unknown
- 2007-04-12 EP EP07728041A patent/EP2012816B1/en active Active
- 2007-04-12 AU AU2007247292A patent/AU2007247292B2/en not_active Ceased
- 2007-04-12 US US12/298,643 patent/US8337828B2/en not_active Expired - Fee Related
- 2007-04-12 CA CA2649063A patent/CA2649063C/en not_active Expired - Fee Related
- 2007-04-12 WO PCT/EP2007/053574 patent/WO2007128647A1/en active Application Filing
- 2007-04-12 PL PL07728041T patent/PL2012816T3/pl unknown
- 2007-04-12 RS RS20120363A patent/RS52377B/en unknown
- 2007-04-12 MX MX2008013872A patent/MX2008013872A/es active IP Right Grant
- 2007-04-12 CN CN2007800159035A patent/CN101437535B/zh not_active Expired - Fee Related
- 2007-04-12 DK DK07728041.0T patent/DK2012816T3/da active
- 2007-04-12 ES ES07728041T patent/ES2389452T3/es active Active
-
2009
- 2009-07-24 HK HK09106795.5A patent/HK1128622A1/xx not_active IP Right Cessation
-
2012
- 2012-08-23 CY CY20121100756T patent/CY1113277T1/el unknown
- 2012-08-24 HR HRP20120676TT patent/HRP20120676T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
SI2012816T1 (sl) | 2012-09-28 |
CA2649063A1 (en) | 2007-11-15 |
JP2009535373A (ja) | 2009-10-01 |
AU2007247292B2 (en) | 2012-04-05 |
RS52377B (en) | 2012-12-31 |
DK2012816T3 (da) | 2012-09-03 |
PL2012816T3 (pl) | 2012-11-30 |
ES2389452T3 (es) | 2012-10-26 |
MX2008013872A (es) | 2008-11-14 |
HRP20120676T1 (hr) | 2012-09-30 |
PT2012816E (pt) | 2012-08-17 |
HK1128622A1 (en) | 2009-11-06 |
US20090275508A1 (en) | 2009-11-05 |
CN101437535B (zh) | 2013-01-30 |
CN101437535A (zh) | 2009-05-20 |
AU2007247292A1 (en) | 2007-11-15 |
US8337828B2 (en) | 2012-12-25 |
EP2012816A1 (en) | 2009-01-14 |
CY1113277T1 (el) | 2016-04-13 |
CA2649063C (en) | 2014-11-25 |
KR101380360B1 (ko) | 2014-04-09 |
JP5441685B2 (ja) | 2014-03-12 |
KR20090007621A (ko) | 2009-01-19 |
EP2012816B1 (en) | 2012-06-27 |
WO2007128647A1 (en) | 2007-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0711136A2 (pt) | uso de timosina alfa1, isoladamente ou em combinação com ptx3 ou ganciclovir, para o tratamento de infeção por citomegalovìrus | |
CL2013001471A1 (es) | Composicion que comprende al menos una n-acetil-lactosamina, al menos un oligosacarido sialilado y al menos un oligosacarido fucosilado y un hidrolizado que comprende proteinas parcialmente y/o completamente hidrolizadas; y su uso para la prevencion y/o tratamiento de las condiciones de la piel y enfermedades de la piel. | |
BRPI0717462A2 (pt) | Emprego de valerato de estradiol ou 17 beta- estradiol em combinação com dienogest na terapia oral para manutenção e/ou aumento da libido feminin | |
CL2007001847A1 (es) | Composicion farmaceutica intramuscular o subcutanea que comprende tmc278 (rilpivirina); proceso para preparar la composicion; y uso para el tratamiento o prevencion de infeccion por vih. | |
MY170607A (en) | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof | |
CL2012003026A1 (es) | Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad. | |
BRPI0708519A8 (pt) | vesícula semelhante ao virossoma, composição farmacêutica, uso de pelo menos uma vesícula semelhante ao virossoma, método de tratamento e/ou profilaxia de uma infecção por hiv, e, kit para induzir uma resposta imune contra uma proteína gp41 de um vírus da imunodeficiência humana | |
PA8807201A1 (es) | Composiciones farmaceuticas | |
CL2007001724A1 (es) | Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1 | |
BRPI0811193A2 (pt) | Proteína de ligação a antígeno isolada, ácido nucleico, célula recombinante, métodos para produzir uma proteína e para proteger ou tratar contra uma infecção por s. aureus em paciente, composição farmacêutica, uso da proteína de ligação a antígeno, e, polipeptídeo. | |
ATE547118T1 (de) | Rekombinanter koi-herpesvirus (khv) oder cyprinid-herpesvirus 3 (cyhv-3) und impfstoff zur prävention einer von khv/cyhv-3 bei cyprinus carpio carpio oder cyprinus carpio koi verursachten erkrankung | |
BR112013029269A8 (pt) | combinação farmacêutica para uso na indução de perda de peso em pacientes com diabetes tipo 2 e/ou para prevenir o ganho de peso em pacientes com diabetes tipo 2 | |
BRPI0510016A (pt) | vetor lentiviral recombinante para expressão de uma proteìna de flaviviridae e aplicações do mesmo como vacina | |
EP2388315A3 (en) | Use of a combination of myxoma virus and rapamycin for therapeutic treatment | |
WO2007104646A3 (en) | Use of the long pentraxin ptx3 for the prevention or treatment of viral diseases | |
CL2007003480A1 (es) | Compuestos derivados de tiazolo[5,4-c]piridin-4-ona sustituida; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento o prevencion de enfermedades relacionadas con la obesidad, como trastornos de la alimentacion, diab | |
BRPI0819839A2 (pt) | Uso de anticorpo humano capaz de neutralizar o vírus da hepatite b para a prevenção ou tratamento da infecção por vírus da hepatite b | |
WO2009068708A8 (es) | Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo | |
BRPI0909910A2 (pt) | "método de tratamento, inibição ou redução da probabilidade de lúpus eritematoso sistêmico (les) ou de um estado de doença secundária, condição ou manifestação associada ao lúpus eritematoso sistêmico ou à púrpura trombocitopênica imunológica em um paciente, composição farmacêutica e seu uso" | |
WO2007027321A3 (en) | Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases | |
EP2193789A4 (en) | USE OF 3,5-DIHYDROTOLUENE OR ITS DERIVATIVES IN THE PREPARATION OF MEDICINAL PRODUCTS OR FUNCTIONAL FOOD FOR THE TREATMENT OR PREVENTION OF DEPRESSION | |
BRPI0418017A (pt) | medicamento compreendendo inibidores de pentraxina ptx3 longa | |
BRPI0418138A (pt) | medicamento compreendendo ptx3, sozinho ou em combinação com tsg-6, para tratar doenças degenerativas de cartilagem e ósseas e tratar infertilidade feminina | |
BR112022004401A2 (pt) | Tratamento de diabetes mellitus tipo 2 | |
BRPI0409711A (pt) | tratamento ou prevenção de infecções respiratórias virais com peptìdeos da alfa timosina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |